# Effect of urea and squaramide IMPDH inhibitors on C. parvum: in vitro trial design impacts the assessment of drug efficacy

**Authors:** Anne-Charlotte Lenière, Amit Upadhyay, Jérôme Follet, Timothy P. O'Sullivan

PMC · DOI: 10.1016/j.ijpddr.2025.100592 · International Journal for Parasitology: Drugs and Drug Resistance · 2025-04-15

## TL;DR

Researchers developed new inhibitors targeting a key enzyme in Cryptosporidium, a parasite causing diarrheal disease, and found some compounds effectively block early stages of infection.

## Contribution

A new family of squaramide-derived IMPDH inhibitors was developed and tested for anti-Cryptosporidium activity.

## Key findings

- Nine active compounds were identified with IC50 values as low as 2.2 μM.
- Active compounds inhibit parasite invasion and early intracellular development.
- Compounds failed to stop parasite growth when introduced 30 hours post-infection.

## Abstract

The protozoan parasite Cryptosporidium is the etiological agent of cryptosporidiosis, a ubiquitous diarrheic disease affecting humans and animals. Treatment options are limited, highlighting an urgent need for novel therapeutics. Despite decades of research and a wide diversity of strategies to tackle parasite metabolic pathways, no completely effective drug has been identified to date. Within targeted parasite enzymatic and metabolic pathways, the synthesis of nucleotide mediated by the inosine 5′-monophosphate dehydrogenase (IMPDH) enzyme is the focus of significant research efforts. Based on our prior studies of bacterial IMPDH inhibitors, we report herein the development and characterisation of novel inhibitors targeting Cryptosporidium parvum IMPDH (CpIMPDH). Specifically, we synthesised heteroaryl-containing urea and squaramide analogues to evaluate their potential in vitro anti-Cryptosporidium activity. Initial screening identified nine active compounds with the most potent candidates achieving IC50 values as low as 2.2 μM. Subsequent time-course experiments revealed that the molecules effectively inhibit parasite invasion and early intracellular development but failed to tackle C. parvum growth when introduced at 30 h post infection. The present work introduces a new family of squaramide-derived IMPDH inhibitors and also interrogates the need to standardise commonly accepted protocols used for assessing anti-cryptosporidial drug activity.

Image 1

•A series of urea and squaramide IMPDH inhibitors were evaluated against C. parvum.•Several compounds displayed potent activity with IC50 values as low as 2.2 μM.•Time-course experiments confirmed that the active compounds inhibit parasite invasion and early intracellular development.

A series of urea and squaramide IMPDH inhibitors were evaluated against C. parvum.

Several compounds displayed potent activity with IC50 values as low as 2.2 μM.

Time-course experiments confirmed that the active compounds inhibit parasite invasion and early intracellular development.

## Linked entities

- **Proteins:** IMPDH (IMP dehydrogenas)
- **Chemicals:** urea (PubChem CID 1176), squaramide (PubChem CID 2781329)
- **Diseases:** cryptosporidiosis (MONDO:0015474)
- **Species:** Cryptosporidium parvum (taxon 5807)

## Full-text entities

- **Diseases:** cryptosporidiosis (MESH:D003457), diarrheic disease (MESH:D004194)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cryptosporidium parvum (species) [taxon 5807]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12123366/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12123366/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12123366/full.md

---
Source: https://tomesphere.com/paper/PMC12123366